Showing results (11-20 of 123) with videos related to
Sort By:
Pageof 13
Acta Dermato-Venereologica|August 1, 1992
Cell kinetics in skin disorders with disturbed keratinizationJ J Rijzewijk, H Groenendal, P van Erp, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 19, 2019
Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MSMinou van Seyen, Marga J A de Graaff Teulen, Nielka P van Erp, et al.Cancer Chemotherapy and Pharmacology|February 21, 2020
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patientsGuillemette E Benoist, Inge M van Oort, David M Burger, et al.The Journal of Investigative Dermatology|August 22, 2000
Low doses of UVB or UVA induce chromosomal aberrations in cultured human skin cellsG Emri, E Wenczl, P Van Erp, et al.Cancer Treatment Reviews|October 2, 2022
Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancerKirti K Iyer, Nielka P van Erp, Daniele V F Tauriello, et al.British Journal of Clinical Pharmacology|February 1, 2018
A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancerGuillemette E Benoist, Maarten J van der Doelen, Rob Ter Heine, et al.Clinical Pharmacology and Therapeutics|October 23, 2023
Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant InteractionJeffrey Strik, Loek A W de Jong, Joost Sijm, et al.Cancer Letters|September 9, 2023
PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancerPeter H J Slootbeek, Joanneke K Overbeek, Marjolijn J L Ligtenberg, et al.Clinical Pharmacokinetics|July 17, 2023
Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-DarolutamideEva Podgoršek, Niven Mehra, Inge M van Oort, et al.European Journal of Endocrinology|January 12, 2011
Mitotane has a strong and a durable inducing effect on CYP3A4 activityNielka P van Erp, Henk-Jan Guchelaar, Bart A Ploeger, et al.Pageof 13